Abstract
Six Chimeric Antigen Receptor-T (CAR-T) therapies have been approved as treatments in relapsed/refractory (R/R) B-cell malignancies since 2017. This study aims to examine patient counts and characteristics of patients on CAR-T therapies in healthcare organizations in the United States covered by the TriNetX network, an electronic medical records (EMR) database.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
